| 2020 | ELI LILLY AND : UBS Adjusts Price Target on Eli Lilly and Co. to $170 From $166,.. | MT |
| 2020 | AbCellera Biologics shares more than triple in stellar debut | RE |
| 2020 | Wolfe Research Upgrades Eli Lilly and Company to Outperform From Peer Perform.. | MT |
| 2020 | Berenberg Adjusts Price Target on Eli Lilly to $150 From $144, Reiterates Hol.. | MT |
| 2020 | Mizuho Securities Adjusts Eli Lilly and Company PT to $156 From $164, Maintai.. | MT |
| 2020 | Bernstein Reinstates Eli Lilly at Market Perform with $150 Price Target | MT |
| 2020 | SHANGHAI JUNSHI BIOSCIENCES : May Benefit From Covid-19 Neutralising Antibody | DJ |
| 2020 | Hospitalized Covid-19 Patients Recovered Faster With Arthritis Drug | DJ |
| 2020 | SPECIAL REPORT : Big Pharma wages stealth war on drug price watchdog | RE |
| 2019 | Teva's new migraine drug helps to contain profit fall | RE |
| 2018 | Trulicity leads mixed third quarter for Lilly; shares sink | RE |
| 2018 | Galapagos, Gilead bask in $4-6 billion new drug sales hope | RE |
| 2018 | Upbeat Roche bests rival Novartis as new drugs fuel growth | RE |
| 2016 | Drugmakers under fire for possible U.S. price fixing | RE |
| 2016 | Drugmaker Sanofi hungry for deals after earnings beat | RE |
| 2016 | Merck gives cautious 2016 outlook as sales of top medicines lag | RE |
| 2015 | ELI LILLY : Lilly beats forecasts on cost cuts, raises 2015 view | RE |
| 2014 | Novartis sales miss forecast as readies overhaul | RE |
| 2014 | Trade group seeks more U.S. pressure on India over patent protection | RE |
| 2014 | ELI LILLY & CO. : Lilly forecasts 2014 profit in line with estimates | RE |
| 2013 | Bribery scandal dents Big Pharma sales in China, GSK hardest hit | RE |
| 2013 | Analysis - Bribery scandal dents Big Pharma sales in China, GSK hardest hit | RE |
| 2013 | Top insulin maker Novo caught up in China's widening drug probes | RE |
| 2013 | Top insulin maker Novo caught up in China's widening drug probes | RE |
| 2013 | ELI LILLY & CO. : Lilly beats forecast, helped by soon-fading Cymbalta | RE |
| 2013 | Pfizer, Lilly beat Street; generics take toll | RE |
| 2013 | ELI LILLY & CO. : Lilly says generic competition hurts fourth-quarter profit, sa.. | RE |
| 2013 | EXCLUSIVE : Disney looks for cost savings, ponders layoffs - sources | RE |
| 2013 | "Cliff" concerns give way to earnings focus | RE |
| 2013 | Alimta patent seen as Lilly's "wild card" | RE |
| 2012 | J&J hit by strong dollar, CEO eyes pruning units | RE |
| 2012 | Pfizer plans animal health IPO | RE |
| 2012 | ELI LILLY & CO. : Lilly quarterly sales, profit beats forecasts | RE |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
